Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

NIHR Health Technology Aassessment is funding a new study looking at the risks and benefits of first line osteoporosis medications (oral bisphosphonates) amongst patients suffering from chronic kidney disease, led by Associate Professor Daniel Prieto-Alhambra of NDORMS.

Around 3 million people suffer from osteoporosis in the UK and about 27% of those have at least moderate chronic kidney disease (CKD).

Osteoporosis weakens bones and makes them fragile and more likely to break. Currently, first line therapies for the prevention of the condition include oral bisphosphonates, a type of drug known to reduce the risk of fracture and improve bone density within 6 months of therapy. However, little is known about the impact of this type of drug on chronic kidney disease.

The new study, to start in December this year, will provide key information on the association between oral bisphosphonates and both the rates of fractures (benefit) and potential side effects amongst patients with different stages of CKD. This will benefit not only patients and but also the NHS: clarifying whether the use of this type of drug is safe and effective in patients with CKD will enable an informed decision on whether UK patients with CKD should be treated with these drugs.

Associate Professor Daniel Prieto-Alhambra says: "Patients with renal impairment have an increased risk of fractures. However, the most commonly used drugs to prevent these could have serious side effects for them. We will use data from thousands of patients with CKD who have been previously exposed to bisphosphonates to determine whether these medications are both safe and effective for them."

The study will use 'real life' data as routinely collected in NHS clinical practice, including primary and hospital care anonymised records for millions of UK people, ensuring the study fully represents the general population of patients. This will make our findings a key piece of information for clinicians treating and patients suffering from kidney impairment considering bisphosphonate therapy across the NHS.

You can read more about this study here.

 

This project is funded by the National Institute for Health Research Health Technology Assessment, with project number 14/36/02: Risks and benefits of bisphosphonate use in patients with chronic kidney disease: a population-based cohort study.

Similar stories

NDORMS researchers awarded for Dupuytren research

Awards Hand Kennedy Main

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF

Arthritis Kennedy Main

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Women's Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.

NDORMS academics named NIHR Senior Investigators

Main

Congratulations to Professor Jonathan Rees who has been announced as a National Institute of Health Research (NIHR Senior Investigator).